When you enter an Indianapolis health clinic that has received federal certification, the first thing you notice is how unremarkable it appears. A clipboard at the front desk, mismatched chairs in the waiting area, and fluorescent lighting. There is no indication that the building is quietly at the heart of one of the state’s most contentious healthcare debates. Nevertheless, it is.
The Indiana Family and Social Services Administration informed dozens of these clinics last week that they would not be affected by a proposed rule that would end a portion of the 340B federal drug discount program for Medicaid reimbursement on July 1. The exemption was presented as a safeguard for Hoosiers with low incomes. Additionally, it is either a reasonable compromise or a political ploy that left the bigger conflict unsolved, depending on who you ask.
One of those federal agreements that virtually no one is aware of until it becomes important is the 340B program itself. Hospitals and eligible clinics that treat a large number of uninsured or low-income patients are permitted to purchase outpatient medications directly from manufacturers at steep discounts. After that, they bill insurance for the entire sum and keep the difference. Theoretically, those savings are put back into non-self-paying services like cancer treatment, behavioral health, and charitable care. In reality, the program has expanded to such an extent that detractors, such as FSSA Secretary Mitch Roob, claim it has strayed greatly from its original intent.
Most accounts describe Roob’s pushback as blunt. He has stated that the program was never intended to increase hospital profits, and in February he suggested eliminating Medicaid reimbursement for medications purchased under the 340B. Instead, the Medicaid Drug Rebate Program would be used by the state to pursue rebates. This type of policy change may seem technical, but keep in mind that actual clinics, actual prescriptions, and actual patients are on the other side of the spreadsheet.
The ensuing pressure was so intense that something had to give. Eventually, federally-qualified medical facilities were established, such as the Jane Pauley Community Health Center in the Indianapolis region. When describing the exemption, Christy Davis, who oversees pharmacy operations at Jane Pauley, didn’t sound victorious. She sounded relieved. In 2025, 9,500 bags of food were distributed by her clinics. They manage pharmacy services, deliver prescriptions, and put patients in touch with rheumatologists and neurologists who would otherwise be months away. She claimed that services would have been discontinued or drastically reduced in the absence of the exemption. Listening to her gives me the impression that this isn’t an abstract policy. It has to do with whether the food pantry remains open.
Gov. Mike Braun’s leadership is responsible for the carve-out, according to Indiana Medicaid Director Audrey Frenzel, who described it as a reaffirmation of his pledge to use public funds responsibly. The official line is that. The unofficial one is that it was politically impossible to close community clinics that catered to the poorest citizens of the state.
However, hospitals received nothing. They are also enraged. The proposal was added to the 2025 budget bill the night before the legislature adjourned, without public discussion, as noted by Scott B. Tittle, president of the Indiana Hospital Association. It’s the kind of detail that sticks. Hospitals contend that because pharmaceutical manufacturers provide the savings, 340B uses no state taxpayer funds. Roob argues that Medicaid is largely dependent on rebate revenue, which vanishes when claims pass through 340B while hospitals continue to bill Medicaid significantly more than their discounted acquisition cost.
Everybody has a point. This is why it’s messy. At a time when an Institute for Clinical and Economic Review analysis revealed a 51% inflation-adjusted increase in net launch prices for 154 new drugs between 2022 and 2024, advocacy groups warn that the change could have real repercussions, including fewer services for the elderly and more cost-shifting to commercial insurance.
It’s difficult to ignore how quickly a discussion about pharmacy billing has evolved into one about who should receive assistance. The exemption was granted to the clinics. The hospitals are still at odds. Many patients are waiting to see which side prevails somewhere in the middle.
